Publication and Public Disclosure Sample Clauses

Publication and Public Disclosure. In accordance with the requirements of this Section 9 (including but not limited to the time-restrictions for “Multi-Center Publications” (Section 9.2), “Confidentiality of Unpublished Data” (Section 9.3)), Institution and Investigator shall have the right to publish or present their Study data following from their own activities conducted under this Agreement. Any proposed publication or presentation shall be consistent with scientific standards by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing Study Results first after the primary source publication of the Sponsor is made public. In addition, Institution and Investigator agree to submit any proposed publication or presentation to Sponsor’s Head of Global Medical Publication, for review at least sixty (60) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within sixty (60) days of its receipt, Sponsor shall advise Institution and/or Investigator, as the case may be, in writing of any information contained therein which is Confidential Information (other than Study Results) or which may impair the availability of patent protection for Inventions. Sponsor shall have the right to require Institution and/or Investigator, as applicable, to remove specifically identified Confidential Information (other than Study Results) and/or to delay the proposed publication or presentation for an additional sixty (60) days to enable Sponsor to seek patent protection for Inventions.
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
Publication and Public Disclosure. In accordance with the requirements of this Section 5 (including but not limited to the time-restrictions for “Multi-Center Publications” (Section 5.2), “Confidentiality of Unpublished Data” (Section 5.3)), Institution and Investigator shall have the right to publish or present their Site Study results following from Site’s own activities conducted under this Agreement,. Any proposed publication or presentation of the Site shall be consistent with scientific standards by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing Site Study Data first after the primary source publication of the Sponsor is made public. In addition, Institution and Investigator agree to submit any proposed publication or presentation to Sponsor’s Head of Global Medical Publication,
Sample 1
Publication and Public Disclosure. In accordance with the requirements of this Section 5 (including but not limited to the time-restrictions for “Multi-Center Publications” (Section 5.2), “Confidentiality of Unpublished Data” (Section 5.3)), Institution and Investigator shall have the right to publish or present their Site Study results following from Site’s own activities conducted under this Agreement. Any proposed publication or presentation of the Site shall be consistent with scientific standards by (i) poprvé do praxe či jakkoli jinak vynalezeny či rozvinuty Poskytovatelem, Zkoušejícím či jakýmkoli jejich zaměstnancem či členem personálu v souvislosti s prováděním Studie.
Sample 1
Publication and Public Disclosure. In accordance with the requirements of this Section 5 (including but not limited to the time-restrictions for “Multi-Center Publications” (Section 5.2), “Confidentiality of Unpublished Data” (Section 5.3)), Institution and Investigator shall have the right to publish or present their Site Study results following from Site’s own activities conducted under this Agreement. Any proposed publication or presentation of the Site shall be consistent with scientific standards by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing Site Study Data first after the primary source publication of the Sponsor is made public. In addition, Institution and Investigator agree to submit any proposed publication or presentation to Sponsor’s, for review at least sixty (60) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within sixty (60) days of its receipt, Sponsor shall advise Institution and/or Investigator, as the case may be, in writing of any information contained therein
Sample 1
Publication and Public Disclosure. In accordance with the requirements of this Section 5 (including but not limited to the time- restrictions for “Multi-Center Publications” (Section 5.2), “Confidentiality of Unpublished Data” (Section 5.3)), Institution and Investigator shall have the right to publish or present their Study results following from activities conducted under this Agreement. Any proposed publication or presentation of the Site shall be consistent with scientific standards by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing Institution´s Study Data first after the primary source publication of the Sponsor is made public. In addition, Institution and Investigator agree to submit any proposed publication or presentation to Sponsor’s Head zastoupení svých zaměstnanců, převede na Zadavatele (nebo přidružený subjekt jmenovaný Zadavatelem) veškerá svá práva, nároky a zájmy k Objevům, včetně všech patentů, autorských děl a jiných práv duševního vlastnictví k tomuto se vztahujícím, jakož i veškerá práva procesní povahy a nároky na náhrady škod a užitky, jež již vznikly v důsledku minulého či současného porušení shora uvedených práv. Poskytovatel se zavazuje, že bude náležitě spolupracovat a poskytne Zadavateli součinnost při vyhotovení a uzavření, a zajistí, že její zaměstnanci vyhotoví a uzavřou, veškeré dokumenty důvodně Zadavatelem požadované za účelem ochrany a zajištění vlastnických práv Zadavatele (nebo přidruženého subjektu jmenovaného Zadavatelem) k
Sample 1
Publication and Public Disclosure. Publication and public disclosure of scientific information shall be governed by Section 3.8 of the MTF processing Agreement.
Sample 1
Publication and Public Disclosure. 5.1 Publikování a zveřejnění In accordance with the requirements of this Section 5 (including but not limited to the time-restrictions for “Multi-Center Publications” (Section 5.2), “Confidentiality of Unpublished Data” (Section 5.3)), Institution and Investigator shall have the right to publish or present their Site Study results following from Site’s own activities conducted under this Agreement. Any proposed publication or presentation of the Site shall be consistent with scientific standards by (i) applying the highest industry standards, including but not limited to the Good Publication Practice and the Recommendations for Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) in their current version and (ii) publishing Site Study Data first after the primary source publication of the Company is made public. In addition, Institution and Investigator agree to submit any proposed publication or presentation to Company’s Head of Global Medical Publication, email address: XxxxxxxXxxxxxxxxxxxx@xxxxxxxxxx.xxx for review at least sixty (60) days prior to submitting any such proposed publication to a publisher or proceeding with such proposed presentation. Within sixty (60) days of its receipt, Company shall advise MS700568_0213 Country: Czech Republic Site No. 602 _PI Name_ Institution name Faculty of Hospital Ostrava Merck_NIS_INST_INV_Agrm_19May2023_From_Merck_Global_ NIS_v1.0_17May2023 Page 16 of 42 V souladu s požadavky tohoto článku 5 (například časová omezení u „Multicentrických publikací“ (článek 5.2), „Důvěrnost nepublikovaných údajů" (článek 5.3)) budou mít Zdravotnické zařízení a Zkoušející právo publikovat nebo prezentovat Výsledky klinického hodnocení dosažené v Místě provádění klinického hodnocení, které vyplývají z vlastních aktivit Místa provádění klinického hodnocení prováděných v rámci této Smlouvy. Veškeré publikace nebo prezentace navrhované Místem provádění klinického hodnocení musejí být v souladu s odbornými standardy, a to tak, že budou (i) uplatňovat nejvyšší standardy v oboru, například správnou publikační praxi a doporučení pro provádění, vykazování, úpravu a zveřejňování vědeckých prací v lékařských časopisech od Mezinárodního výboru vydavatelů lékařských časopisů (ICMJE) v aktuální verzi a (ii) publikovat Údaje ze Studie z Místa provádění klinického hodnocení až poté, co Společnost zveřejní primární zdrojovou publikaci. Kromě toho Zdravo...
Sample 1
AutoNDA by SimpleDocs

Related to Publication and Public Disclosure

  • PUBLICATION AND PUBLICITY The CONSULTANT agrees that it shall not for any reason whatsoever communicate to any third party in any manner whatsoever concerning any of its CONTRACT work product, its conduct under the CONTRACT, the results or data gathered or processed under this CONTRACT, which includes, but is not limited to, reports, computer information and access, drawings, studies, notes, maps and other data prepared by and for the CONSULTANT under the terms of this CONTRACT, without prior written approval from the COMMISSION, unless such release or disclosure is required by judicial proceeding. The CONSULTANT agrees that it shall immediately refer any third party who requests such information to the COMMISSION and shall also report to the COMMISSION any such third party inquiry. This Article shall not apply to information in whatever form that comes into the public domain, nor shall it restrict the CONSULTANT from giving notices required by law or complying with an order to provide information or data when such order is issued by a court, administrative agency or other authority with proper jurisdiction, or if it is reasonably necessary for the CONSULTANT to defend itself from any suit or claim. All approved releases of information, findings, and recommendations shall include a disclaimer provision and all published reports shall include that disclaimer on the cover and title page in the following form: The opinions, findings, and conclusions in this publication are those of the author(s) and not necessarily those of the Mississippi Department of Transportation, Mississippi Transportation Commission, the State of Mississippi or the Federal Highway Administration.

  • No Public Disclosure The Company shall not disclose any holder of Investor Units’ name or identity as an investor in the Company in any press release or other public announcement or in any document or material filed with any governmental entity, without the prior written consent of such Person, unless such disclosure is required by applicable law or governmental regulations or by order of a court of competent jurisdiction, in which case prior to making such disclosure the Company shall give written notice to such Person describing in reasonable detail the proposed content of such disclosure and shall permit such Person to review and comment upon the form and substance of such disclosure.

  • Review of Public Disclosures All SEC filings (including, without limitation, all filings required under the Exchange Act, which include Forms 10-Q and 10-QSB, 10-K and 10K-SB, 8-K, etc) and other public disclosures made by the Company, including, without limitation, all press releases, investor relations materials, and scripts of analysts meetings and calls, shall be reviewed and approved for release by the Company’s attorneys and, if containing financial information, the Company’s independent certified public accountants.

  • Press Releases and Public Announcements No Party shall issue any press release or make any public announcement relating to the subject matter of this Agreement without the prior written approval of the other Party; provided, however, that any Party may make any public disclosure it believes in good faith is required by applicable law or any listing or trading agreement concerning its publicly-traded securities (in which case the disclosing Party will use its reasonable best efforts to advise the other Party prior to making the disclosure).

  • Public Disclosures The Company shall not, nor shall it permit any Subsidiary to, disclose any Investor’s name or identity as an investor in the Company in any press release or other public announcement or in any document or material filed with any governmental entity (other than tax filings in the ordinary course), without the prior written consent of such Investor, unless such disclosure is required by applicable law or governmental regulations or by order of a court of competent jurisdiction, in which case prior to making such disclosure the Company shall give written notice to such Investor describing in reasonable detail the proposed content of such disclosure and shall permit such Investor to review and comment upon the form and substance of such disclosure.

  • Public Disclosure Parent and Company will consult with each other and agree before issuing any press release or otherwise making any public statement with respect to the Merger, this Agreement or an Acquisition Proposal and will not issue any such press release or make any such public statement prior to such agreement, except as may be required by law or any listing agreement with a national securities exchange, in which case reasonable efforts to consult with the other party will be made prior to any such release or public statement. The parties have agreed to the text of the joint press release announcing the signing of this Agreement.

  • Confidentiality and Public Announcements (a) Neither Party may disclose the contents of this Agreement or any information concerning negotiations leading to this Agreement and the Transaction, without the prior written consent of the other Party. Nothing contained in this Agreement shall prevent a Party from disclosing such information: (i) to any Governmental Authority or to the public, but in either case, only if and to the extent that such disclosure is required under any Applicable Law or any stock exchange rule or policy to which such Party or its Affiliate is subject; (ii) to obtain consents required under, or to comply with any ROFRs or other preferential, pre- emptive or first purchase rights contained in, the Title and Operating Documents and any other agreements and documents to which the Assets are subject; or (iii) if required to obtain the consent to the Transaction by Vendor’s lenders or other security holders and, if applicable, to obtain their release of Security Interests in, or their acknowledgement of “no interest” in, the Assets; provided that, in each such instance, the Party that proposes to make such a disclosure shall advise the other Party of such proposed disclosure and shall use its reasonable efforts to prevent the disclosure of any such information that is not required to be disclosed for the listed purposes. This Section 9.12(a) shall survive any termination of this Agreement prior to Closing for a period of one (1) year following such termination. (b) The Parties acknowledge that either or both of them may make press releases concerning the Parties’ entry into this Agreement promptly after the execution hereof and further press releases promptly after Closing, provided that in no circumstances shall either Party disclose the name of the other Party in any such press release or otherwise. Each Party consents to the inclusion of a generic description of its businesses by the other Party in such other Party’s press release(s) in this regard. The Parties agree that a press release issued by either Party may contain some or all of the financial terms of the Transaction. Without derogating from the Parties’ rights to make public disclosures under Section 9.12(a), each of Vendor and Purchaser shall use its reasonable efforts to furnish to the other Party with the proposed content of all press releases concerning this Agreement and the Transaction at least twenty-four (24) hours prior to the release or publication thereof, but in any event prior to the release or publication with reasonably sufficient time for the other Party to review and comment.

  • Prohibition on Press Releases and Public Announcements The Company shall not issue press releases or engage in any other publicity, without the Representative’s prior written consent, for a period ending at 5:00 p.m., Eastern time, on the first (1st) Business Day following the forty-fifth (45th) day after the Closing Date, other than normal and customary releases issued in the ordinary course of the Company’s business.

  • Confidentiality and Publication 7.1 Except as provided herein, each party shall maintain in confidence during the term of this Agreement and for seven (7) years thereafter, and shall not use for any [*] Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. purpose or disclose to any third party, any Technology or other information disclosed by the other party in writing and marked "Confidential" or that is disclosed orally and confirmed in writing as confidential within forty-five (45) days following such disclosure (collectively, 'CONFIDENTIAL INFORMATION'), except to the extent that any such Confidential Information - (a) is at the time of being so provided or after that time through no fault of the party to whom it was so provided becomes public knowledge; or (b) was lawfully available on a non-confidential basis to the party to whom it was so provided before that time; or (c) can be shown by the party to whom it was so provided to have been independently produced by that party without any use of such confidential information provided to it by the other party; or (d) is made available to the party to whom it was so provided otherwise than in breach of an obligation of confidentiality owed to the other party. 7.2 The results of the Project may be made public by either party (or, in the case of ICRT, by ICRF) except to the extent that - (a) publication would include any Confidential Information of the other party; or (b) publication would prejudice the obtaining of patent protection for an invention constituting Project Technology, or the commercial exploitation of any unpatented or unpatentable Project Technology which remains unpublished. 7.3 To allow time for review of any proposed disclosure of any subject matter which may be precluded from being made public under clause 7.2, each of ICRT and Introgen shall provide to the other - (a) a copy of any manuscript disclosing any results of the Project not less than 45 days notice before submitting the manuscript for publication; and (b) a copy of any slides to be used in an oral presentation disclosing any results of the Project together with an outline of the presentation not less than 20 working days before making any such oral presentation. 7.4 The party receiving any such material pursuant to clause 7.3 shall promptly and in any event prior to the proposed date of submission for publication review the proposed disclosure and notify the other party in writing of its conclusions, failing which the other party shall be free to make the proposed disclosure. 7.5 If in the reasonable opinion of the party receiving the material the proposed disclosure does not include subject matter which is precluded from being made public under clause 7.2, it shall promptly notify the other party which shall thereupon be free to make the proposed disclosure. 7.6 If in the reasonable opinion of either party - (a) the proposed disclosure includes subject matter which is precluded from being made public under clause 7.2 and which is patentable, neither party shall publish or otherwise disclose the material in question for a period of three months from the date on which the relevant material was received by the party in question and, if a patent application is made within that period of three months, for a further period as agreed but in any event not exceeding a total of 18 months from that date (including such period of three months), following which the other party shall be free to make the proposed disclosure; or (b) the proposed disclosure includes unpatented (or unpatentable) Project Technology which that party wishes to maintain as unpublished and which (c) the proposed disclosure includes Confidential Information of the reviewing party, the disclosing party shall remove such Confidential Information prior to such disclosure. 7.7 Notwithstanding the foregoing provisions of this clause 7 above, the receiving party may use or disclose Confidential Information of the disclosing party (a) to the extent necessary to exercise its rights hereunder (including providing such information to bona fide licensees or prospective licensees as contemplated by this Agreement or otherwise and to potential investors or partners on reasonable terms of confidentiality) or to fulfil its obligations and/or duties hereunder; (b) in filing for, prosecuting or maintaining any proprietary rights, prosecuting or defending litigation; and (c) in complying with applicable governmental regulations and/or submitting information to tax or other governmental authorities; or as otherwise required by law; provided that if the receiving party is required by law to make any public disclosures of Confidential Information of the disclosing party then, to the extent it may legally do so, it shall give reasonable advance notice to the disclosing party of such disclosure and shall use its reasonable efforts to secure confidential treatment of

  • Confidentiality; Public Disclosure (a) Each of the Agents and the Lenders agrees to keep confidential all non-public information provided to it by any Loan Party pursuant to this Agreement that is designated by such Loan Party as confidential; provided that nothing herein shall prevent any Agent or any Lender from disclosing any such information (i) to any Agent, any other Lender or any affiliate of any thereof, (ii) to any Participant or Assignee (each, a “Transferee”) or prospective Transferee that agrees to comply with the provisions of this Section or substantially equivalent provisions, (iii) any of its employees, directors, agents, attorneys, accountants and other professional advisors, (iv) any financial institution that is a direct or indirect contractual counterparty in swap agreements or such contractual counterparty’s professional advisor (so long as such contractual counterparty or professional advisor to such contractual counterparty agrees to be bound by the provisions of this Section), (v) upon the request or demand of any Governmental Authority having jurisdiction over it, (vi) in response to any order of any court or other Governmental Authority or as may otherwise be required pursuant to any Requirement of Law, (vii) in connection with any litigation or similar proceeding, (viii) that has been publicly disclosed other than in breach of this Section, (ix) to the National Association of Insurance Commissioners or any similar organization or any nationally recognized rating agency that requires access to information about a Lender’s investment portfolio in connection with ratings issued with respect to such Lender or (x) in connection with the exercise of any remedy hereunder or under any other Loan Document. (b) None of the Loan Parties shall issue any press release or other public disclosure (other than any filing required to be made with the SEC) using the name of any of the Lenders or any affiliate of a Lender in connection with this transaction without both (i) providing any such Lender with at least two (2) Business Days’ prior notice and (ii) obtaining the Lender’s or such Lender’s affiliate’s prior written consent. Nothing in the immediately preceding sentence shall prevent any disclosure of the name of any Lender or of any affiliate of such Lender to the extent (and only to the extent) required by any Requirement of Law, provided that, the person or entity making such disclosure shall nonetheless consult with the affected Lender or the relevant affiliate of such Lender prior to issuing such press release or other public disclosure. (c) Notwithstanding the foregoing, the Lenders and their Affiliates shall have the right to (i) list and exhibit the Borrower’s name and logo, as provided by the Borrower from time to time, and describe the transaction that is the subject of this Agreement in their marketing materials and (ii) post such information, including, without limitation, a customary “tombstone,” on their web site.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!